Poland· PL-100333371

Copaxone

A glatiramer acetate product containing glatirameri acetas, registered in Poland by TEVA GmbH. The same ATC class is registered in 14 of our 19 countries.

ATC L03AX13

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedCopaxoneATCL03AX13REGISTER NO.PL-100333371PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Glatiramer acetate is registered in 14 of 19 countries.

Countries holding a registration under ATC L03AX13 (glatiramer acetate), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose

Glatiramer acetate · ATC L03AX13

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Glatirameri acetas
Manufacturer
TEVA GmbH
Country
Poland (PL)
ATC code
L03AX13
ATC class
Glatiramer acetate
Defined daily dose
20 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991216375
  • gtin
    05909991216382
  • gtin
    05909991216399

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for glatiramer acetate.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Glatiramer acetate · interactions on record

2 records

  • 2 severe

Most severe, free to view

  • NatalizumabL04AA23severe
  • NatalizumabL04AG03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/30edc376-b912-4aca-91ec-63b7c5a6eeb9
GET /v1/drugs/30edc376-b912-4aca-91ec-63b7c5a6eeb9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
  "source": "urpl",
  "strength": "40 mg/ml",
  "packaging": "05909991216375 ¦ Rp ¦ 107787\n3 amp.-strzyk. 1 ml\n05909991216382 ¦ Rp ¦ 107788\n12 amp.-strzyk. 1 ml\n05909991216399 ¦ Rp ¦ 107789\n36 amp.-strzyk. 1 ml (3 op. x 12 amp.-strzyk.)",
  "substance": "Glatirameri acetas 40 mg/ml",
  "common_name": "Glatirameri acetas",
  "pl_product_id": "100333371",
  "pozwolenie_nr": "22364",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}

See everything about glatiramer acetate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.